7 completed, 1 terminated, 1 withdrawn. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 7, Terminated 1, Withdrawn 1 |
Follow LY2140023: new trials by email Literature Review of LY2140023 trials Research Report on LY2140023
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A mGlu2/3 Agonist in the Treatment of PTSD Pomaglumetad Methionil 160mg, Pomaglumetad Methionil 40mg, Placebo - Post-traumatic Stress Disorder | Phase 1 | Terminated | NYU Langone Health | 10 | 2014-09-01 | 2018-11-02 |
| A Study of LY2140023 in Healthy Participants LY2140023 - Healthy Participants | Phase 1 | Withdrawn | Denovo Biopharma LLC | 2012-08-01 | 2021-08-23 | |
| A Study of LY2140023 in Healthy Participants LY2140023, 14C-LY2140023, 14C-LY404039 - Healthy Participants | Phase 1 | Completed | Denovo Biopharma LLC | 18 | 2012-07-01 | 2021-09-21 |
| A Study of LY2140023 in Healthy Participants LY2140023, Aqueous activated charcoal - Healthy Volunteer Study | Phase 1 | Completed | Denovo Biopharma LLC | 27 | 2012-06-01 | 2021-09-21 |
| A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia LY2140023, Placebo, Moxifloxacin - Schizophrenic Disorders | Phase 1 | Completed | Denovo Biopharma LLC | 86 | 2012-06-01 | 2023-04-03 |
| A Study of LY2979165 and LY2140023 in Healthy Volunteers LY2979165, LY2140023, Placebo - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 52 | 2012-04-01 | 2013-08-02 |
| A Study of LY2140023 in Hepatically-Impaired Participants LY2140023 - Hepatic Insufficiency | Phase 1 | Completed | Denovo Biopharma LLC | 37 | 2011-11-01 | 2021-09-22 |
| The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects Ammonium Chloride + LY2140023, Sodium Bicarbonate + LY2140023, LY2140023 - Healthy Subjects | Phase 1 | Completed | Denovo Biopharma LLC | 29 | 2011-09-01 | 2026-09-15 |
| A Study of Safety and Tolerability in Subjects With Schizophrenia LY2140023, Aripiprazole - Schizophrenia | Phase 1 | Completed | Denovo Biopharma LLC | 75 | 2011-05-01 | 2022-09-14 |
Schizophrenia (2) · Hepatic Insufficiency (1) · Stress Disorders, Post-Traumatic (1)
Denovo Biopharma LLC (7) · Eli Lilly and Company (1) · NYU Langone Health (1)
United Kingdom (4) · United States (2) · Germany (1) · Hungary (1) · Switzerland (1)